Page last updated: 2024-08-17

bromodeoxyuridine and Ventricular Dysfunction, Left

bromodeoxyuridine has been researched along with Ventricular Dysfunction, Left in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Esaki, M; Fujiwara, H; Fujiwara, T; Goto, K; Hayakawa, K; Kawase, Y; Koda, M; Kosai, K; Li, Y; Maruyama, R; Minatoguchi, S; Mizuguchi, H; Nagano, S; Okada, H; Takahashi, T; Takemura, G; Yuge, K	1

Other Studies

1 other study(ies) available for bromodeoxyuridine and Ventricular Dysfunction, Left

Article	Year
Postinfarction treatment with an adenoviral vector expressing hepatocyte growth factor relieves chronic left ventricular remodeling and dysfunction in mice. Circulation, 2003, May-20, Volume: 107, Issue:19 Topics: Adenoviridae; Animals; Bromodeoxyuridine; Cell Division; Chronic Disease; Disease Models, Animal; Disease Progression; Genetic Vectors; Hepatocyte Growth Factor; Hepatocytes; Humans; Immunohistochemistry; Male; Mice; Mice, Inbred C57BL; Myocardial Infarction; Myocardium; Survival Rate; Time Factors; Transduction, Genetic; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Remodeling	2003

Article

Year

Postinfarction treatment with an adenoviral vector expressing hepatocyte growth factor relieves chronic left ventricular remodeling and dysfunction in mice.

Circulation, 2003, May-20, Volume: 107, Issue:19

Topics: Adenoviridae; Animals; Bromodeoxyuridine; Cell Division; Chronic Disease; Disease Models, Animal; Disease Progression; Genetic Vectors; Hepatocyte Growth Factor; Hepatocytes; Humans; Immunohistochemistry; Male; Mice; Mice, Inbred C57BL; Myocardial Infarction; Myocardium; Survival Rate; Time Factors; Transduction, Genetic; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Remodeling

2003